A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF BASMISANIL (RO5186582) AS ADJUNCTIVE TREATMENT IN PATIENTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS

Investigator: Dante Durand

Institutional Protocol #: 20160898

National Clinical Trials Identifier: 02953639

Funding Agency/Sponsor: ROCHE PHARM

Division: Psychiatry

Therapeutic Area: Other

Phase: N/A

Enrolling Sites: University of Miami Medical Group

Enrolling Since: 7/11/2017


Purpose/Abstract:

N/A

Eligibility Criteria:

N/A
Please note that this is written for scientific review, and if there are any questions or clarifications needed, please contact

Gabriela Vargas, Project Manager, Research Support
(305) 243 2708
gvargas3@miami.edu

Back    


E-mail a Friend